vs
Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $233.0M, roughly 1.2× CSW INDUSTRIALS, INC.). CSW INDUSTRIALS, INC. runs the higher net margin — 4.4% vs -45.7%, a 50.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 20.3%). CSW INDUSTRIALS, INC. produced more free cash flow last quarter ($22.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CSW vs GH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $233.0M | $281.3M |
| Net Profit | $10.3M | $-128.5M |
| Gross Margin | 39.7% | 64.6% |
| Operating Margin | 7.4% | -43.0% |
| Net Margin | 4.4% | -45.7% |
| Revenue YoY | 20.3% | 39.4% |
| Net Profit YoY | -61.9% | -15.8% |
| EPS (diluted) | $0.62 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $233.0M | $281.3M | ||
| Q3 25 | $277.0M | $265.2M | ||
| Q2 25 | $263.6M | $232.1M | ||
| Q1 25 | $230.5M | $203.5M | ||
| Q4 24 | $193.6M | $201.8M | ||
| Q3 24 | $227.9M | $191.5M | ||
| Q2 24 | $226.2M | $177.2M | ||
| Q1 24 | $210.9M | $168.5M |
| Q4 25 | $10.3M | $-128.5M | ||
| Q3 25 | $40.7M | $-92.7M | ||
| Q2 25 | $40.9M | $-99.9M | ||
| Q1 25 | $35.1M | $-95.2M | ||
| Q4 24 | $26.9M | $-111.0M | ||
| Q3 24 | $36.1M | $-107.8M | ||
| Q2 24 | $38.6M | $-102.6M | ||
| Q1 24 | $31.8M | $-115.0M |
| Q4 25 | 39.7% | 64.6% | ||
| Q3 25 | 43.0% | 64.7% | ||
| Q2 25 | 43.8% | 65.0% | ||
| Q1 25 | 44.2% | 63.3% | ||
| Q4 24 | 41.4% | 61.6% | ||
| Q3 24 | 45.6% | 61.1% | ||
| Q2 24 | 47.5% | 59.1% | ||
| Q1 24 | 44.4% | 61.2% |
| Q4 25 | 7.4% | -43.0% | ||
| Q3 25 | 20.5% | -37.3% | ||
| Q2 25 | 20.8% | -45.9% | ||
| Q1 25 | 19.5% | -54.6% | ||
| Q4 24 | 15.3% | -62.4% | ||
| Q3 24 | 22.6% | -61.3% | ||
| Q2 24 | 24.3% | -56.8% | ||
| Q1 24 | 21.0% | -59.2% |
| Q4 25 | 4.4% | -45.7% | ||
| Q3 25 | 14.7% | -35.0% | ||
| Q2 25 | 15.5% | -43.0% | ||
| Q1 25 | 15.2% | -46.8% | ||
| Q4 24 | 13.9% | -55.0% | ||
| Q3 24 | 15.8% | -56.3% | ||
| Q2 24 | 17.1% | -57.9% | ||
| Q1 24 | 15.1% | -68.2% |
| Q4 25 | $0.62 | $-1.01 | ||
| Q3 25 | $2.41 | $-0.74 | ||
| Q2 25 | $2.43 | $-0.80 | ||
| Q1 25 | $2.05 | $-0.77 | ||
| Q4 24 | $1.60 | $-0.90 | ||
| Q3 24 | $2.26 | $-0.88 | ||
| Q2 24 | $2.47 | $-0.84 | ||
| Q1 24 | $2.03 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.2M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $1.1B | $-99.3M |
| Total Assets | $2.3B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.2M | $378.2M | ||
| Q3 25 | $31.5M | $580.0M | ||
| Q2 25 | $38.0M | $629.1M | ||
| Q1 25 | $225.8M | $698.6M | ||
| Q4 24 | $213.8M | $525.5M | ||
| Q3 24 | $273.2M | $585.0M | ||
| Q2 24 | $18.9M | $933.7M | ||
| Q1 24 | $22.2M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | $800.1M | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
| Q4 25 | $1.1B | $-99.3M | ||
| Q3 25 | $1.1B | $-354.5M | ||
| Q2 25 | $1.1B | $-305.5M | ||
| Q1 25 | $1.1B | $-250.8M | ||
| Q4 24 | $1.0B | $-139.6M | ||
| Q3 24 | $1.0B | $-60.1M | ||
| Q2 24 | $650.2M | $-1.6M | ||
| Q1 24 | $615.7M | $68.3M |
| Q4 25 | $2.3B | $2.0B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.0B | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-26.4M |
| Free Cash FlowOCF − Capex | $22.7M | $-54.2M |
| FCF MarginFCF / Revenue | 9.8% | -19.3% |
| Capex IntensityCapex / Revenue | 2.6% | 9.9% |
| Cash ConversionOCF / Net Profit | 2.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $162.0M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.9M | $-26.4M | ||
| Q3 25 | $61.8M | $-35.4M | ||
| Q2 25 | $60.6M | $-60.3M | ||
| Q1 25 | $27.3M | $-62.7M | ||
| Q4 24 | $11.6M | $-64.5M | ||
| Q3 24 | $66.8M | $-51.1M | ||
| Q2 24 | $62.7M | $-94.0M | ||
| Q1 24 | $22.4M | $-30.3M |
| Q4 25 | $22.7M | $-54.2M | ||
| Q3 25 | $58.7M | $-45.8M | ||
| Q2 25 | $57.7M | $-65.9M | ||
| Q1 25 | $22.8M | $-67.1M | ||
| Q4 24 | $8.5M | $-83.4M | ||
| Q3 24 | $61.3M | $-55.3M | ||
| Q2 24 | $59.6M | $-99.1M | ||
| Q1 24 | $17.5M | $-37.2M |
| Q4 25 | 9.8% | -19.3% | ||
| Q3 25 | 21.2% | -17.3% | ||
| Q2 25 | 21.9% | -28.4% | ||
| Q1 25 | 9.9% | -33.0% | ||
| Q4 24 | 4.4% | -41.3% | ||
| Q3 24 | 26.9% | -28.9% | ||
| Q2 24 | 26.3% | -55.9% | ||
| Q1 24 | 8.3% | -22.1% |
| Q4 25 | 2.6% | 9.9% | ||
| Q3 25 | 1.1% | 3.9% | ||
| Q2 25 | 1.1% | 2.4% | ||
| Q1 25 | 2.0% | 2.2% | ||
| Q4 24 | 1.6% | 9.4% | ||
| Q3 24 | 2.4% | 2.2% | ||
| Q2 24 | 1.4% | 2.9% | ||
| Q1 24 | 2.3% | 4.1% |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
